signal transducer and activator of transcription 5BGenealiases: GHISID2 · STAT5
Q-omics provides the consensus-scored STAT5B profile across patient tissues and cancer cell-line models. STAT5B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAT5B is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, STAT5B protein abundance shows 21,791 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where STAT5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAT5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAT5B survival associations across molecular data types. STAT5B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAT5B RNA expression–survival associations across cancer types. High STAT5B expression shows unfavorable associations in CESC, but favorable associations in KIRC, BRCA, SKCM, PAAD and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAT5B RNA expression.
This table summarizes STAT5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STAT5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAT5B shows lower tumor expression in BLCA, LUSC, LUAD, UCEC and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher STAT5B RNA expression in normal versus tumor tissue (log2 FC = −1.674, t-test p < 0.001).
This table shows molecular features associated with STAT5B in patient tissues and cancer cell lines. In patient samples, STAT5B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STAT5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
